openPR Logo
Press release

Pulmonary Arterial Hypertension (PAH) Market by Key Players 

08-18-2017 06:07 PM CET | Health & Medicine

Press release from: Transparency Market Research

Pulmonary Arterial Hypertension (PAH) Market by Key Players 

Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot

Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure for PAH available in the market, which renders the market highly opportunistic. According to a report by Transparency Market Research (TMR), the global PAH market is estimated to reach a valuation of US$5.19 bn by the end of 2020, expanding at a tremendous CAGR of 17.90% between 2014 and 2020.

View Report @ http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html

Several treatments are available to control symptoms, slow down the progression of the disease, and enhance the quality of life. The approval of some effective drugs in recent times and the presence of a promising pipeline are among the primary factors providing a significant boost to the global pulmonary arterial hypertension market. Favorable government initiatives are also playing a vital role in the development of the market.

A TMR analyst states that however, the patent expiry of some of the blockbuster drugs are paving way for penetration of generic drugs. Generic drugs are usually 70% to 80% cheaper than branded drugs and therefore, their increased sales adversely affect the overall revenue generation of the market. On the other hand, the future of the global market looks bright with the development of cutting-edge therapies for the treatment of PAH.

Prostacyclin and Prostacyclin Analogs to Rise to Forefront during Forecast Period

On the basis of drug class, the report segments the global PAH market into PDE-5 inhibitors, endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, and soluble guanylate cyclase (sGC) stimulators and selexipag. The ERAs segment dominated the market in terms of value at the beginning of the forecast period. However, by the end of this period, the prostacyclin and prostacyclin analogs segment will surpass ERAs. The growth of the segment can be mainly attributed to the approval of new drugs such as Uptravi (selexipag) in December 2015 and Orenitram (treprostinil) in December 2013. While in the case of sGC stimulator, Adempas (riociguat) is the only approved drug for the treatment of PAH.

Availability of Newly-approved PAH Drugs to Fuel Dominance of North America

North America will continue to account for the lion’s share until 2020, closely trailed by Europe. These two developed regions will exhibit remarkable growth during the forecast period, thanks to the availability of newly-approved PAH drugs along with the presence of a promising pipeline. The high awareness among the populace regarding the availability of treatment for pulmonary arterial hypertension is also driving the growth of the regions.

Get accurate market forecast and analysis on the Pulmonary Arterial Hypertension. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

The Asia Pacific market will also be highly opportunistic in nature. Countries such as Japan, Australia, India, New Zealand, and China will be sights of high growth rates in the region and therefore, will be emerging destinations for global players. Rest of the World, on the other hand, is likely to register sluggish growth during the same period. The lack of awareness related to the detection and treatment of PAH is acting as a bottleneck in the development of the region.

Some of the prominent participants in the global pulmonary arterial hypertension market are Gilead Sciences Inc., Actelion Pharmaceuticals Ltd., GlaxoSmithKline Plc., Bayer HealthCare, Novartis International AG, Pfizer Inc., and United Therapeutics Corp. 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Arterial Hypertension (PAH) Market by Key Players  here

News-ID: 675243 • Views:

More Releases from Transparency Market Research

Point-of-Care Glucose Testing Market: Technological Innovations Shaping the Future
Point-of-Care Glucose Testing Market: Technological Innovations Shaping the Futu …
The global healthcare industry is undergoing a technological revolution, and Point-of-Care (POC) glucose testing is at the forefront of this transformation. As diabetes continues to impact millions of lives worldwide, the need for efficient, accurate, and timely glucose monitoring has become critical. Newly released data from Transparency Market Research reveals that the global POC glucose testing market was valued at USD 3.7 billion in 2021 and is expected to reach USD
Dental Dust Collector Market: Regional Insights and Forecasts to 2031
Dental Dust Collector Market: Regional Insights and Forecasts to 2031
The dental dust collector market has been witnessing significant growth as the dental industry places a greater emphasis on occupational safety and adopts advanced technology. Dental dust collectors play a crucial role in creating a clean and safe environment in dental clinics and laboratories by capturing harmful airborne particles produced during procedures such as drilling, grinding, and polishing. Access key findings and insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85310 These devices
Vacuum Insulation Panels Market Size Will Anticipated to Reach US$ 12.6 Billion, Grow at a CAGR of 4.8% by 2031 | Transparency Market Research Inc.
Vacuum Insulation Panels Market Size Will Anticipated to Reach US$ 12.6 Billion, …
The vacuum insulation panels (VIPs) market represents a vital component in the global push for energy efficiency and thermal insulation solutions. VIPs are advanced thermal insulating materials that offer superior performance compared to traditional insulation products. These panels, composed of a core material enclosed within a gas-tight envelope, are widely used across industries, including construction, refrigeration, and logistics, where high thermal resistance is critical. It is estimated to grow at a
Aviation Lubricants Market Outlook 2031: Expanding from US$ 991.8 Million to US$ 1.6 Billion with an 5.4% CAGR
Aviation Lubricants Market Outlook 2031: Expanding from US$ 991.8 Million to US$ …
The aviation lubricants market is a crucial segment within the aerospace industry, encompassing specialized oils, greases, and fluids designed to enhance the performance and reliability of aircraft systems. These lubricants are essential for ensuring operational efficiency, reducing wear and tear, and maintaining safety standards across commercial, military, and general aviation sectors. It is estimated to grow at a CAGR of 5.4% from 2023 to 2031 and reach US$ 1.6 Bn by

All 5 Releases


More Releases for PAH

Development: Pulmonary Arterial Hypertension (PAH) Market Growth Analysis
The global pulmonary arterial hypertension (pah) market is estimated to surpass $9,670.2 million by 2027, exhibiting a CAGR of 5.8% from 2020 to 2027. The report provides all-inclusive analysis of global pulmonary arterial hypertension (pah) market with comprehensive study of the various facets of the market including market dynamics, major segments and regions, top leading players, and competitive landscape. Research Methodology Research Dive offers its clients extensive research and analysis gleaned from wide
Pulmonary Arterial Hypertension (PAH) Market Research and Clinical Analysis 2020
Global Pulmonary Arterial Hypertension (PAH) Market research report published by market insight reports explores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters. This Pulmonary Arterial Hypertension (PAH) Market research report identifies the competitive landscape of industries to understand the competition at International level.
Pulmonary Arterial Hypertension (PAH) Medicine Market (2020-2027) Report Offers …
The research study includes the latest updates about the COVID-19 impact on the Pulmonary Arterial Hypertension (PAH) Medicine sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy. The market research report on the global Pulmonary Arterial Hypertension (PAH) Medicine market provides an extensive and
Pulmonary Arterial Hypertension (PAH) - Market Outlook and Competitive Landscape …
Report Overview  The report provides a comprehensive view of disease events, types, severity, progression, symptoms, risk factors, pathogenesis and treatment guidelines at country level  Comprehensive insight on patient segmentation has been provided into the epidemiology of the Pulmonary Arterial Hypertension (PAH) and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China  Drug utilization and analysis on the current
Global Pulmonary Arterial Hypertension (PAH) Market| MarketResearchReports.biz
Latest industry research report on: Global Pulmonary Arterial Hypertension (PAH) Market : Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global Pulmonary Arterial Hypertension (PAH) market on the basis of Drug Class (Endothelin Receptor Antagonists, Prostacyclin, Prostacyclin Analogs, Phosphodiesterase V
Pulmonary Arterial Hypertension (PAH) Market by Key Players 
Global Pulmonary Arterial Hypertension (PAH) Market: Snapshot Pulmonary arterial hypertension (PAH) is a very rare type of progressive disorder related to high blood pressure. However, the rate of incidence of this disorder is gradually gaining traction. Various sources, including WHO and CDC, suggest that the global prevalence of PAH is anticipated to be between 100,000 and 200,000, narrowing down to about 15-50 cases per million heads. There is no permanent cure